Biotech startups that raised Series B in Shanghai, China
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Enjosim | Shanghai | Series B | $30.1M | 2026-11-02 |
| Bluesail Surgical | Shanghai | Series B | $104.5M | 2026-09-23 |
| MindRank AI | Shanghai | Series B | $52.0M | 2026-07-08 |
| Bivision | Shanghai | Series B | $58.8M | 2026-05-18 |
| Novamab | Shanghai | Series B | $43.9M | 2026-04-24 |
| Alioth | Shanghai | Series B | $14.4M | 2026-01-15 |
| Epigenic Therapeutics | Shanghai | Series B | $60.0M | 2025-09-07 |
| Rona Therapeutics | Shanghai | Series B | $25.0M | 2025-03-14 |
8 rows of the CSV in 5 of its 18 columns.
- The 53 biotech startups in Shanghai, China whose last round is Series B have raised $1.9B in total.
- 11 of them closed their most recent round in the last 12 months, $440.7M combined.
- The largest of those rounds is Bluesail Surgical's $104.5M Series B, dated September 2026.
- The most recent is Enjosim's $30.1M Series B on 2 November 2026.
- Huagai Capital is an investor in 2 of them, more than any other fund.
- Health care is the most common other sector, with 47 companies (89%).
- 26% were founded in 2020 or later; the median founding year is 2017.
- The most common team size is 11 to 50 employees (37% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
6 of 53| Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|
| Enjosim | Enjosim researches, manufactures, and sells self-delivery systems for biomacromolecule pharmaceuticals. | Biotech | Series B | $30.1M | 2026-11-02 | $30.1M | Luminous Ventures (former Lightspeed China Partners), Jiayuan Capital | 51 to 100 | 2021 |
| Bluesail Surgical | Bluesail Surgical develops surgical instruments for cardiovascular treatments. | Biotech | Series B | $104.5M | 2026-09-23 | $245.4M | Huagai Capital, Linkong Private Equity Fund Management, Linqu County High-Tech Industrial Investment | 101 to 250 | 2020 |
| MindRank AI | MindRank AI develops artificial intelligence platforms to discover and develop small molecule drugs. | Artificial intelligence | Series B | $52.0M | 2026-07-08 | $101.0M | Green Pine Capital Partners, Huagai Capital, Sherpa Healthcare Partners +1 | 11 to 50 | 2020 |
| Bivision | Bivision researches and develops targeted radiopharmaceuticals for therapy. | Biotech | Series B | $58.8M | 2026-05-18 | $100.9M | Gaorong Capital, Kaitai Capital, Lichen Capital | 11 to 50 | 2021 |
| Novamab | Novamab researches and develops new nanobodies. | Biotech | Series B | $43.9M | 2026-04-24 | $97.8M | Qiming Venture Partners, Taiyu Investment, Fuho Capital +1 | 51 to 100 | 2017 |
| Alioth | Alioth develops and applies technical products for pharmaceutical process technology. | Biotech | Series B | $14.4M | 2026-01-15 | $54.7M | Matrix Partners China, Legend Capital | 51 to 100 | 2021 |
Table 1. Biotech startups that raised Series B in Shanghai, China: the 6 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 53.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Bluesail Surgical | Bluesail Surgical develops surgical instruments for cardiovascular treatments. | Biotech | Series B | $104.5M | 2026-09-23 | $245.4M | Huagai Capital, Linkong Private Equity Fund Management, Linqu County High-Tech Industrial Investment | 101 to 250 | 2020 |
| 2 | Bivision | Bivision researches and develops targeted radiopharmaceuticals for therapy. | Biotech | Series B | $58.8M | 2026-05-18 | $100.9M | Gaorong Capital, Kaitai Capital, Lichen Capital | 11 to 50 | 2021 |
| 3 | MindRank AI | MindRank AI develops artificial intelligence platforms to discover and develop small molecule drugs. | Artificial intelligence | Series B | $52.0M | 2026-07-08 | $101.0M | Green Pine Capital Partners, Huagai Capital, Sherpa Healthcare Partners +1 | 11 to 50 | 2020 |
| 4 | Novamab | Novamab researches and develops new nanobodies. | Biotech | Series B | $43.9M | 2026-04-24 | $97.8M | Qiming Venture Partners, Taiyu Investment, Fuho Capital +1 | 51 to 100 | 2017 |
| 5 | Enjosim | Enjosim researches, manufactures, and sells self-delivery systems for biomacromolecule pharmaceuticals. | Biotech | Series B | $30.1M | 2026-11-02 | $30.1M | Luminous Ventures (former Lightspeed China Partners), Jiayuan Capital | 51 to 100 | 2021 |
| 6 | Alioth | Alioth develops and applies technical products for pharmaceutical process technology. | Biotech | Series B | $14.4M | 2026-01-15 | $54.7M | Matrix Partners China, Legend Capital | 51 to 100 | 2021 |
Table 2. Biotech startups that raised Series B in Shanghai, China: the 6 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Huagai Capital | Private equity firm | Beijing, China | 2 | 4% | 2 | Bluesail Surgical, MindRank AI |
| 2 | Sherpa Healthcare Partners | Venture capital firm | Beijing, China | 2 | 4% | 1 | MindRank AI |
| 3 | Qiming Venture Partners | Venture capital firm | Shanghai, China | 2 | 4% | 1 | Novamab |
| 4 | Taiyu Investment | Venture capital firm | Beijing, China | 2 | 4% | 1 | Novamab |
| 5 | Luminous Ventures (former Lightspeed China Partners) | Venture capital firm | Shanghai, China | 1 | 2% | 1 | Enjosim |
| 6 | Jiayuan Capital | Family office | Futian, China | 1 | 2% | 1 | Enjosim |
| 7 | Linqu County High-Tech Industrial Investment | 1 | 2% | 1 | Bluesail Surgical | ||
| 8 | Linkong Private Equity Fund Management | 1 | 2% | 1 | Bluesail Surgical | ||
| 9 | Green Pine Capital Partners | Venture capital firm | Shenzhen, China | 1 | 2% | 1 | MindRank AI |
| 10 | CHERAMI | Private equity firm | Guangzhou, China | 1 | 2% | 1 | MindRank AI |
| 11 | GL Ventures LLC | Venture capital firm | Beijing, China | 1 | 2% | 1 | Etern |
| 12 | CICC | Investment bank | Beijing, China | 1 | 2% | 1 | Etern |
| 13 | Hillhouse Investment | Angel group | Singapore | 1 | 2% | 1 | Etern |
| 14 | Wuxi Capital | Angel group | Wuxi Shi, China | 1 | 2% | 1 | Etern |
| 15 | 5Y Capital | Venture capital firm | Xuhui, China | 1 | 2% | 1 | Etern |
Table 3. Biotech startups that raised Series B in Shanghai, China: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 47 | 89% | $1.9B |
| Artificial intelligence | 3 | 6% | $101.0M |
| Software | 3 | 6% | $101.0M |
| Hardware | 1 | 2% | |
| Fintech | 1 | 2% | |
| Energy | 1 | 2% |
Table 4. Biotech startups that raised Series B in Shanghai, China by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series B | 53 | 100% | $30.0M |
Table 5. Biotech startups that raised Series B in Shanghai, China by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 1 | 9% | $30.1M |
| September 2026 | 2 | 18% | $184.5M |
| July 2026 | 1 | 9% | $52.0M |
| June 2026 | 1 | 9% | |
| May 2026 | 1 | 9% | $58.8M |
| April 2026 | 2 | 18% | $58.5M |
| March 2026 | 1 | 9% | $14.2M |
| January 2026 | 1 | 9% | $14.4M |
| December 2025 | 1 | 9% | $28.4M |
Table 6. Biotech startups that raised Series B in Shanghai, China: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 10 | 19% | $412.3M |
| 2025 | 6 | 11% | $127.3M |
| 2024 | 2 | 4% | |
| 2023 | 6 | 11% | $72.0M |
| 2022 | 8 | 15% | $174.3M |
| 2021 | 11 | 21% | $690.6M |
Table 7. Biotech startups that raised Series B in Shanghai, China by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2020 to 2022 | 14 | 26% |
| 2015 to 2019 | 24 | 45% |
| 2010 to 2014 | 12 | 23% |
| Before 2010 | 3 | 6% |
Table 8. Biotech startups that raised Series B in Shanghai, China by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 2 | 4% |
| 11 to 50 | 19 | 37% |
| 51 to 100 | 13 | 25% |
| 101 to 250 | 9 | 18% |
| 251 to 500 | 4 | 8% |
| 501 to 1,000 | 2 | 4% |
| 1,001 to 5,000 | 2 | 4% |
Table 9. Biotech startups that raised Series B in Shanghai, China by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series B and its headquarters is in Shanghai, China. On 16 November 2026 that is 53 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 6 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 53 rows: 14 have no round amount, 0 no city and 13 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in Shanghai, China whose last round is Series B are on the list?
- 53, in the file dated 16 November 2026. 11 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 53 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.